OriCiro Genomics is a genome technology company looking at applications for synthetic biology. The company focuses on the development and commercialization of next-generation technologies of large DNA synthesis and amplification. One of company's core technologies enables cell-free, thereby efficient and easy-to-use amplification of large DNA molecules replacing conventional E. coli cloning. OriCiro was established in December 2018, located in Tokyo, and closed Series A financing in March 2019 raising $3.6M from a Japanese VC, UTEC (University of Tokyo Edge Capital). Company’s mission is to create a better Bioeconomy with innovate genome technologies. What the company offers includes reagent kits for large DNA amplification and assembly for academia research, and technology licensing to CDMOs for plasmid DNA manufacturing. We also look at co-development arrangements with partners from the pharma, diagnostics, agriculture and industrial biotech companies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Reagent kit for cell-free amplification and assembly of large DNA
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):